Diffuse Large B-Cell Lymphoma (DLBCL) Latest Advances

Dual targeting of EZH2 and DOT1L in DLBCL.

Journal: Blood

Published: April 17, 2025

Syncope in a patient with a right atrial tumour of diffuse large B-cell lymphoma.

Journal: BMJ case reports

Published: April 15, 2025

Efficacy and Safety of Rituximab plus Modified EPOCH (Etoposide, Vincristine, Doxorubicin, Carboplatin, and Prednisolone) for Transplant-ineligible Relapsed/Refractory Diffuse Large B-cell Lymphoma.

Journal: Internal medicine (Tokyo, Japan)

Published: April 13, 2025

CD3×CD20 bispecifics + chemotherapy: good news for R/R DLBCL.

Journal: Blood

Published: April 10, 2025

Corrigendum to "Epstein-Barr Virus-Encoded Latent Membrane Protein 2A Promotes Immune Escape by Upregulating SYK/Nuclear Factor-κB Signaling in Diffuse Large B-cell Lymphoma" [Laboratory Investigation 105 (2025) 104104].

Journal: Laboratory investigation; a journal of technical methods and pathology

Published: April 09, 2025

Glofitamab results in cost savings versus epcoritamab in relapsed/refractory diffuse large B-cell lymphoma: a total cost of care analysis‡.

Journal: Leukemia & lymphoma

Published: April 09, 2025

Contemporary management of diffuse large B-cell lymphoma in Japan.

Journal: Expert review of anticancer therapy

Published: April 07, 2025

Phase I Study of Subcutaneous Rituximab Hyaluronidase Combined With CHOP Chemotherapy for the Treatment of Diffuse Large B-Cell Lymphoma in Uganda.

Journal: JCO global oncology

Published: April 04, 2025

Clinical issues and perspectives in diffuse large B-cell lymphoma based on 15 years of clinical studies by the Kyoto Hematology Clinical Research Group (KOTOSG)

Journal: [Rinsho ketsueki] The Japanese journal of clinical hematology

Published: April 02, 2025

MiR-93 promotes the progression and chemoresistance of diffuse large B-cell lymphoma cells via targeting SMAD5.

Journal: Archives of physiology and biochemistry

Published: April 01, 2025

The journey of patients with diffuse large B-cell lymphoma: from symptoms to diagnosis.

Journal: Leukemia & lymphoma

Published: March 31, 2025

Real-world treatment patterns, healthcare resource use, and costs among patients with diffuse large B-cell lymphoma: a retrospective analysis of US claims data.

Journal: Leukemia & lymphoma

Published: March 31, 2025

Customize your search results with filters

Dual targeting of EZH2 and DOT1L in DLBCL.

Dual targeting of EZH2 and DOT1L in DLBCL.

Syncope in a patient with a right atrial tumour of diffuse large B-cell lymphoma.

Syncope in a patient with a right atrial tumour of diffuse large B-cell lymphoma.

Efficacy and Safety of Rituximab plus Modified EPOCH (Etoposide, Vincristine, Doxorubicin, Carboplatin, and Prednisolone) for Transplant-ineligible Relapsed/Refractory Diffuse Large B-cell Lymphoma.

Efficacy and Safety of Rituximab plus Modified EPOCH (Etoposide, Vincristine, Doxorubicin, Carboplatin, and Prednisolone) for Transplant-ineligible Relapsed/Refractory Diffuse Large B-cell Lymphoma.

CD3×CD20 bispecifics + chemotherapy: good news for R/R DLBCL.

CD3×CD20 bispecifics + chemotherapy: good news for R/R DLBCL.

Corrigendum to "Epstein-Barr Virus-Encoded Latent Membrane Protein 2A Promotes Immune Escape by Upregulating SYK/Nuclear Factor-κB Signaling in Diffuse Large B-cell Lymphoma" [Laboratory Investigation 105 (2025) 104104].

Corrigendum to "Epstein-Barr Virus-Encoded Latent Membrane Protein 2A Promotes Immune Escape by Upregulating SYK/Nuclear Factor-κB Signaling in Diffuse Large B-cell Lymphoma" [Laboratory Investigation 105 (2025) 104104].

Glofitamab results in cost savings versus epcoritamab in relapsed/refractory diffuse large B-cell lymphoma: a total cost of care analysis‡.

Glofitamab results in cost savings versus epcoritamab in relapsed/refractory diffuse large B-cell lymphoma: a total cost of care analysis‡.

Contemporary management of diffuse large B-cell lymphoma in Japan.

Contemporary management of diffuse large B-cell lymphoma in Japan.

Phase I Study of Subcutaneous Rituximab Hyaluronidase Combined With CHOP Chemotherapy for the Treatment of Diffuse Large B-Cell Lymphoma in Uganda.

Phase I Study of Subcutaneous Rituximab Hyaluronidase Combined With CHOP Chemotherapy for the Treatment of Diffuse Large B-Cell Lymphoma in Uganda.

Clinical issues and perspectives in diffuse large B-cell lymphoma based on 15 years of clinical studies by the Kyoto Hematology Clinical Research Group (KOTOSG)

Clinical issues and perspectives in diffuse large B-cell lymphoma based on 15 years of clinical studies by the Kyoto Hematology Clinical Research Group (KOTOSG)

MiR-93 promotes the progression and chemoresistance of diffuse large B-cell lymphoma cells via targeting SMAD5.

MiR-93 promotes the progression and chemoresistance of diffuse large B-cell lymphoma cells via targeting SMAD5.

The journey of patients with diffuse large B-cell lymphoma: from symptoms to diagnosis.

The journey of patients with diffuse large B-cell lymphoma: from symptoms to diagnosis.

Real-world treatment patterns, healthcare resource use, and costs among patients with diffuse large B-cell lymphoma: a retrospective analysis of US claims data.

Real-world treatment patterns, healthcare resource use, and costs among patients with diffuse large B-cell lymphoma: a retrospective analysis of US claims data.